Issue 26, 2026, Issue in Progress

Heteroatom-doped reduced graphene oxide electrochemical sensor for sensitive dopamine detection with preliminary clinical evaluation of neurotransmitter dysregulation in pediatric epilepsy

Abstract

Monitoring dopamine (DA) levels in biological fluids is highly informative for the early diagnosis and therapeutic management of neurological disorders such as Parkinson's disease, schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and epilepsy, which represents a major pediatric neurological condition with wide clinical heterogeneity. In this study, we report a preliminary clinical evaluation of an electrochemical sensor developed for DA detection in the blood of pediatric epilepsy patients. The sensing platform is based on screen-printed carbon electrodes (SPCEs) modified with nitrogen-doped reduced graphene oxide (N-RGO) and nitrogen/sulfur co-doped reduced graphene oxide (S/N-RGO) to enhance electrocatalytic performance. Heteroatom incorporation into RGO significantly improved electron transfer kinetics, electroactive surface area, and sensing activity. Using chronoamperometry (CA) and differential pulse voltammetry (DPV), the N-RGO sensor achieved low detection limits of 6.8 nM and 7.9 nM, respectively, in buffer, with excellent selectivity in the presence of common interferents such as ascorbic acid and uric acid. High recovery rates (∼100%) were obtained in commercial plasma and fresh human serum samples, including those collected from pediatric epilepsy patients. Notably, DA plasma concentrations were found to be lower in this heterogeneous group of epileptic patients, reflecting neurotransmitter dysregulation associated with epilepsy subtype and antiepileptic treatment (valproate). This work presents a sensitive electrochemical sensor capable of detecting and monitoring DA in blood and highlights its potential as a minimally invasive point-of-care tool for pediatric epileptic patients. With further development, this device could also be applied to assess DA levels in other neurological disorders.

Graphical abstract: Heteroatom-doped reduced graphene oxide electrochemical sensor for sensitive dopamine detection with preliminary clinical evaluation of neurotransmitter dysregulation in pediatric epilepsy

Supplementary files

Article information

Article type
Paper
Submitted
18 Dec 2025
Accepted
26 Mar 2026
First published
06 May 2026
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2026,16, 23443-23454

Heteroatom-doped reduced graphene oxide electrochemical sensor for sensitive dopamine detection with preliminary clinical evaluation of neurotransmitter dysregulation in pediatric epilepsy

F. Besbes, Z. Hsine, S. Galai, I. Kraoua, R. Mlika and H. Korri-Youssoufi, RSC Adv., 2026, 16, 23443 DOI: 10.1039/D5RA09797E

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements